These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27216827)

  • 41. Immunization in children with chronic renal failure: a practical approach.
    Neuhaus TJ
    Pediatr Nephrol; 2004 Dec; 19(12):1334-9. PubMed ID: 15503181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist.
    Friedman MA; Winthrop KL
    Rheum Dis Clin North Am; 2017 Feb; 43(1):1-13. PubMed ID: 27890167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The spread of vaccine-preventable diseases by international travellers: a public-health concern.
    Gautret P; Botelho-Nevers E; Brouqui P; Parola P
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():77-84. PubMed ID: 22862565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Student health policy of a German medical school--results of a cross sectional study concerning students' immunity to vaccine-preventable diseases.
    Schmid K; Wallaschofski H; Drexler H
    Int J Hyg Environ Health; 2004 Dec; 207(6):595-600. PubMed ID: 15729842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

  • 46. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Meyer S; Forleo-Neto E; Gniel D; Dagnew AF; Arora AK
    Travel Med Infect Dis; 2014; 12(5):485-93. PubMed ID: 24873986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel vaccine concept based on back-boost effect in viral infection.
    Kohler H
    Vaccine; 2015 Jun; 33(29):3274-5. PubMed ID: 26032350
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pediatric immunization update 2002.
    Paulson PR; Hammer AL
    Pediatr Nurs; 2002; 28(2):173-81. PubMed ID: 11962186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.
    Prasad RM; Srivastava S; Wang E; Liu JZ; Gami R; Abdelgadir A; Sharma A; Rayamajhi S; Tikaria R
    Perm J; 2021 Oct; 26(1):123-131. PubMed ID: 35609158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunizations in adult patients with systemic sclerosis.
    Launay O; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2009 Sep; 1173():610-8. PubMed ID: 19758206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The medically immunocompromised adult traveler and pre-travel counseling: status quo 2014.
    Askling HH; Dalm VA
    Travel Med Infect Dis; 2014; 12(3):219-28. PubMed ID: 24821082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunizations in children on PD: current guidelines and recommendations.
    Fivush BA; Furth SL; Neu AM
    Adv Perit Dial; 1995; 11():270-3. PubMed ID: 8534720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab Use in Pediatric Dermatology.
    Hoffman MB; Bhandari RA; Sinha AA
    J Drugs Dermatol; 2016 Jul; 15(7):821-9. PubMed ID: 27391631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maternal benefits of immunization during pregnancy.
    Swamy GK; Beigi RH
    Vaccine; 2015 Nov; 33(47):6436-40. PubMed ID: 26384445
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What timing of vaccination is potentially dangerous for children younger than 2 years?
    Gras P; Bailly AC; Lagrée M; Dervaux B; Martinot A; Dubos F
    Hum Vaccin Immunother; 2016 Aug; 12(8):2046-2052. PubMed ID: 27215704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positive immunomodulatory effects of heterologous DNA vaccine- modified live vaccine, prime-boost immunization, against the highly-pathogenic PRRSV infection.
    Sirisereewan C; Nedumpun T; Kesdangsakonwut S; Woonwong Y; Kedkovid R; Arunorat J; Thanawongnuwech R; Suradhat S
    Vet Immunol Immunopathol; 2017 Jan; 183():7-15. PubMed ID: 28063479
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine-preventable outbreaks: still with us after all these years.
    Ruderfer D; Krilov LR
    Pediatr Ann; 2015 Apr; 44(4):e76-81. PubMed ID: 25875983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine-preventable infection morbidity of patients with chronic kidney disease and cocoon vaccination strategies.
    Bitsori M; Galanakis E
    Expert Rev Vaccines; 2015; 14(10):1385-95. PubMed ID: 26289972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation.
    Patel SR; Ortín M; Cohen BJ; Borrow R; Irving D; Sheldon J; Heath PT
    Clin Infect Dis; 2007 Mar; 44(5):625-34. PubMed ID: 17278051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.